Impact of the French COVID-19 pandemic lockdown on newly diagnosed melanoma delay and severity

J Eur Acad Dermatol Venereol. 2022 Mar;36(3):e164-e166. doi: 10.1111/jdv.17802. Epub 2021 Nov 23.

Authors

R Molinier¹, A Roger^{1

2}, B Genet³, A Blom^{1

2}, C Longvert^{1

2}, L Chaplain¹, M Fort¹, P Saiag^{1

2}, E Funck-Brentano^{1

2}

Affiliations

¹ Department of General and Oncologic Dermatology, Ambroise-Paré hospital, AP-HP, Boulogne-Billancourt, France.
² Research unit EA4340 "Biomarkers and clinical trials in oncology and onco-hematology", Versailles-Saint-Quentin-en-Yvelines University, Paris-Saclay University, Versailles, France.
³ Department of Statistics and Methodology on Biomedical Research, Kremlin-Bicêtre University, Paris-Saclay University, Le Kremlin-Bicêtre, France.

No abstract available

Publication types

Letter

MeSH terms

COVID-19*
Communicable Disease Control
Humans
Melanoma* / diagnosis
Melanoma* / epidemiology
Pandemics
SARS-CoV-2